• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Molecular epidemiology and population immunity of SARS-CoV-2 in Guangdong (2022-2023) following a pivotal shift in the pandemic

tetano

Editor, Senior Moderator
Nat Commun


. 2024 Aug 15;15(1):7033.
doi: 10.1038/s41467-024-51141-y. Molecular epidemiology and population immunity of SARS-CoV-2 in Guangdong (2022-2023) following a pivotal shift in the pandemic

Zhencui Li[SUP] #[/SUP][SUP] 1 2 [/SUP], Pei Hu[SUP] #[/SUP][SUP] 1 [/SUP], Lin Qu[SUP] #[/SUP][SUP] 1 3 4 [/SUP], Mingda Yang[SUP] #[/SUP][SUP] 1 4 5 [/SUP], Ming Qiu[SUP] #[/SUP][SUP] 1 3 4 [/SUP], Chunyan Xie[SUP] 1 4 5 [/SUP], Haiyi Yang[SUP] 1 3 4 [/SUP], Jiadian Cao[SUP] 1 3 4 [/SUP], Lina Yi[SUP] 1 4 [/SUP], Zhe Liu[SUP] 1 4 [/SUP], Lirong Zou[SUP] 1 2 [/SUP], Huimin Lian[SUP] 1 4 6 [/SUP], Huiling Zeng[SUP] 1 4 7 [/SUP], Shaojian Xu[SUP] 8 [/SUP], Pengwei Hu[SUP] 9 [/SUP], Jiufeng Sun[SUP] 1 4 [/SUP], Jianfeng He[SUP] 1 [/SUP], Liang Chen[SUP] 1 4 [/SUP], Ying Yang[SUP] 1 4 [/SUP], Baisheng Li[SUP] 10 11 [/SUP], Limei Sun[SUP] 12 [/SUP], Jing Lu[SUP] 13 14 15 [/SUP]



Affiliations
Abstract

The SARS-CoV-2 Omicron variant sparked the largest wave of infections worldwide. Mainland China eased its strict COVID-19 measures in late 2022 and experienced two nationwide Omicron waves in 2023. Here, we investigated lineage distribution and virus evolution in Guangdong, China, 2022-2023 by comparing 5813 local viral genomes with the datasets from other regions of China and worldwide. Additionally, we conducted three large-scale serological surveys involving 1696 participants to measure their immune response to the BA.5 and XBB.1.9 before and after the corresponding waves. Our findings revealed the Omicron variants, mainly the BA.5.2.48 lineage, causing infections in over 90% of individuals across different age groups within a month. This rapid spread led to the establishment of widespread immunity, limiting the virus's ability to further adaptive mutation and dissemination. While similar immune responses to BA.5 were observed across all age groups after the initial wave, children aged 3 to 11 developed a stronger cross immune response to the XBB.1.9 strain, possibly explaining their lower infection rates in the following XBB.1 wave. Reinfection with Omicron XBB.1 variant triggered a more potent neutralizing immune response among older adults. These findings highlight the impact of age-specific immune responses on viral spread in potential future waves.


 
Back
Top Bottom